Comprehensive Clinical Development Review: Lotiglipron (PF-07081532)

1. Introduction to Lotiglipron (PF-07081532)

Lotiglipron, identified by the code PF-07081532, was an investigational, orally administered, small-molecule therapeutic agent developed by Pfizer Inc..[1] It belongs to the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class of drugs.[3] The intended therapeutic indications for lotiglipron were the management of Type 2 Diabetes Mellitus (T2D) and obesity.[1]

The development of lotiglipron represented an effort to provide a convenient oral alternative to the widely successful injectable peptide-based GLP-1 RAs, such as semaglutide and liraglutide, which dominate the treatment landscape for T2D and obesity.[2] Pfizer pursued the development of lotiglipron concurrently with another oral small-molecule GLP-1 RA, danuglipron (PF-06882961).[1] This parallel development strategy suggested a high perceived value in capturing a share of the oral metabolic drug market, while also acknowledging the inherent risks and challenges in bringing such a novel small-molecule agent through clinical trials successfully. Despite initial promise, the clinical development of lotiglipron was ultimately discontinued by Pfizer in June 2023 due to safety concerns.[1]

2. Mechanism of Action and Therapeutic Rationale

Lotiglipron functions as an agonist at the glucagon-like peptide-1 receptor (GLP-1R).[3] GLP-1 RAs exert their therapeutic effects by mimicking the actions of the endogenous incretin hormone GLP-1.[1] Activation of the GLP-1R leads to several physiological responses beneficial for metabolic control: it enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses the release of glucagon from pancreatic alpha cells (particularly during hyperglycemia), slows the rate of gastric emptying which reduces postprandial glucose excursions, and promotes satiety signals in the central nervous system, leading to reduced appetite and food intake.[1] These combined actions result in improved glycemic control in patients with T2D and contribute to significant weight loss in individuals with obesity.

The therapeutic rationale for developing lotiglipron stemmed from the well-established efficacy and broad clinical benefits of the GLP-1 RA class.[4] By creating an orally bioavailable small molecule, Pfizer aimed to overcome the administration barrier associated with injectable peptide GLP-1 RAs, potentially improving patient adherence and accessibility.[2] Lotiglipron's small-molecule nature represented a distinct chemical approach compared to the modified peptide structures of existing GLP-1 RAs.[3]

However, developing potent, selective, and safe small-molecule agonists for complex class B G protein-coupled receptors like the GLP-1R presents considerable pharmacological challenges.[3] Unlike peptide drugs that often closely mimic the natural ligand, small molecules must achieve agonism through potentially different binding modes and interactions within the receptor pocket. This increases the complexity of predicting off-target effects or unique pharmacological properties that might lead to unforeseen safety issues. The specific chemical structure of lotiglipron, while successfully activating the GLP-1R, may have inadvertently interacted with other biological pathways, particularly in the liver, contributing to the liver enzyme elevations that ultimately led to its discontinuation.

3. Clinical Development Program Overview

Pfizer initiated a clinical development program for lotiglipron encompassing Phase 1 and Phase 2 studies to evaluate its safety, tolerability, pharmacokinetics (PK), and efficacy in target populations.

• Phase 1 Studies: The program included multiple-ascending-dose (MAD) studies designed to assess the safety, tolerability, PK, and preliminary efficacy signals of lotiglipron in participants with T2D (often on a stable metformin background) and in participants with obesity but without diabetes. Key Phase 1 MAD trials registered include NCT04305587 and NCT05158244.[4] Additionally, specific Phase 1 drug-drug interaction (DDI) studies (NCT05671653, NCT05788328) were conducted to evaluate potential interactions with other medications.[1]
• Phase 2 Study: Following Phase 1, a dose-ranging Phase 2 study (NCT05579977) was initiated to further evaluate the efficacy and safety of lotiglipron across a range of doses in participants with T2D or obesity.[5]

Discontinuation: Despite progressing into Phase 2, the entire clinical development program for lotiglipron was terminated by Pfizer in June 2023.[1] The reasons cited were related to safety findings, specifically elevated liver enzymes, observed in the clinical trials.[1]

Table 1: Lotiglipron Clinical Trial Overview

MAD: Multiple Ascending Dose; PK: Pharmacokinetics; HbA1c: Glycated Hemoglobin; T2D: Type 2 Diabetes.

4. Phase 1 Clinical Trial Findings (NCT04305587, NCT05158244)

The initial Phase 1 multiple-ascending-dose studies evaluated lotiglipron in participants with T2D and/or obesity without diabetes, administering target doses up to 180 mg once daily over periods of 28 or 42 days.[4]

• Pharmacokinetics (PK): A key finding from these early studies was the pharmacokinetic profile, which demonstrated suitability for once-daily oral administration.[4] This was a potentially advantageous feature compared to Pfizer's other oral GLP-1 RA candidate, danuglipron, which was initially being developed with a twice-daily dosing schedule.[8]
• Efficacy: Preliminary efficacy signals were encouraging. In participants with T2D treated for 42 days, the 180 mg once-daily dose led to a least squares (LS) mean decrease from baseline in HbA1c of -1.61% (compared to -0.61% for placebo). Dose-dependent reductions in mean daily glucose were also observed. Significant weight loss was noted in both populations; the T2D cohort showed an LS mean decrease of -5.10 kg at 180 mg (vs. -2.06 kg for placebo) after 42 days, with similar weight loss magnitudes reported in the obesity cohort.[4]
• Safety and Tolerability: Initial reports characterized the safety profile as generally consistent with the known mechanism of action for GLP-1 RAs. The majority of adverse events (AEs) were reported as mild (89.6%), with nausea being the most common.[4] Published abstracts summarizing these Phase 1 MAD studies did not specifically highlight clinically meaningful adverse trends in safety laboratory results, including liver enzymes.[6] This initial reporting contrasts with the liver enzyme elevations later cited as the primary reason for program discontinuation.[1] The discrepancy suggests that the liver safety signal may have been less apparent in the shorter-duration Phase 1 MAD studies, potentially emerging or becoming a clearer concern with longer exposure durations, analysis of larger datasets including the Phase 2 trial, or specifically within the context of the drug-drug interaction studies.

5. Phase 2 Clinical Trial Findings (NCT05579977)

The Phase 2 dose-ranging study (NCT05579977) aimed to further characterize the efficacy and safety of lotiglipron across various doses (up to 80 mg in T2D, up to 200 mg in obesity) and titration schedules.[5]

• Efficacy: The study confirmed the efficacy signals observed in Phase 1.
• Glycemic Control (T2D): At week 16, all lotiglipron doses produced statistically significant reductions in HbA1c compared to placebo (p < 0.0001). The LS mean decrease reached -1.44% (90% CI: -1.63, -1.26) with the 80 mg dose, compared to -0.07% with placebo.[5]
• Weight Loss (Obesity): At week 20, all lotiglipron doses resulted in statistically significant decreases in body weight compared to placebo (p < 0.01). The LS mean decrease was up to -7.47% (90% CI: -8.50, -6.43) with the 200 mg dose (using a five-step titration), compared to -1.84% with placebo.[5]
• Safety and Tolerability: While efficacy was confirmed, Phase 2 data also highlighted significant safety and tolerability challenges.
• Gastrointestinal Events: Consistent with the GLP-1 RA class, gastrointestinal AEs were the most common, primarily mild to moderate. Nausea incidence was notably high, reaching up to 28.8% in the T2D cohort (80 mg dose) and up to 60.6% in the obesity cohort (200 mg dose, four-step titration), compared to 4%-12.5% in placebo groups.[5] The study abstract noted that a majority of participants assigned to higher doses did not reach their target maintenance dose, suggesting that GI tolerability likely limited effective dose escalation for many individuals.[5]
• Liver Enzyme Elevations: Crucially, the Phase 2 study reported a higher incidence of transaminase elevations compared to placebo, reinforcing the safety signal observed in Phase 1 DDI studies. The incidence was 6.6% in the T2D cohort and 6.0% in the obesity cohort receiving lotiglipron, versus 1.6% in the obesity placebo group.[5]

The Phase 2 results painted a mixed picture: confirmed efficacy for glycemic control and weight loss, but hampered by significant GI tolerability issues affecting dose attainment and, more critically, the emergence of a concerning liver safety signal.[5]

6. Safety Profile Analysis: Focus on Liver Enzyme Elevations

The observation of elevated liver transaminases became the pivotal safety concern leading to the termination of the lotiglipron program. This signal was detected across multiple studies, including the Phase 1 DDI trials (NCT05671653, NCT05788328) and the Phase 2 dose-ranging trial (NCT05579977).[1]

• Incidence: Data from the Phase 2 trial (NCT05579977) indicated an incidence of transaminase elevations of 6.0% to 6.6% in lotiglipron-treated participants, compared to 1.6% in the placebo arm (obesity cohort).[5]
• Clinical Presentation: Pfizer consistently reported that these enzyme elevations were asymptomatic. No participants experienced liver-related symptoms, side effects, liver failure, or required medical intervention due to these findings.[1]
• Comparison to Danuglipron (as of June 2023): When announcing lotiglipron's discontinuation, Pfizer specifically noted that similar transaminase elevations had not been observed in the clinical program for danuglipron, which at that point included data from over 1,400 participants.[1] This distinction initially supported the decision to prioritize danuglipron.
• Significance: Despite being asymptomatic, the higher incidence of liver enzyme elevations with lotiglipron compared to placebo raised significant safety concerns. For drugs intended for chronic administration in large patient populations with metabolic diseases, regulatory bodies maintain a low tolerance for potential hepatotoxicity signals. Even asymptomatic elevations can be precursors to more severe drug-induced liver injury (DILI). Furthermore, the Phase 2 study report mentioned that attempts to identify the specific population at risk for these elevations were unsuccessful.[5] This unpredictability likely made it impossible to establish a clear risk mitigation strategy or define a safe therapeutic window, rendering the overall risk-benefit profile unfavorable for continued development.[1]

Table 2: Summary of Key Adverse Events (Lotiglipron vs. Placebo in Phase 2 - NCT05579977)

Incidence rates represent the maximum reported for any lotiglipron dose group within the specified cohort in the source abstract.

7. Discontinuation of Lotiglipron Development

On June 26, 2023, Pfizer officially announced the discontinuation of the entire clinical development program for lotiglipron.[1] The decision was primarily driven by the observation of elevated liver transaminases in patients enrolled in the Phase 1 DDI studies (NCT05671653, NCT05788328) and the ongoing Phase 2 dose-ranging study (NCT05579977).[1] Pharmacokinetic data obtained from the Phase 1 studies also contributed to the decision.[1]

Pfizer reiterated that the observed enzyme elevations were asymptomatic and did not result in liver failure or necessitate treatment.[1] However, the safety signal was deemed significant enough to halt the program, likely reflecting concerns about potential long-term liver toxicity with chronic use in a broad patient population. Following this discontinuation, Pfizer confirmed its intention to focus its resources on advancing its other oral GLP-1 RA candidate, danuglipron.[1]

8. Context and Conclusion

The development trajectory of lotiglipron illustrates the significant hurdles in translating the success of injectable peptide GLP-1 RAs into safe and effective oral small-molecule therapies. While Phase 1 and early Phase 2 data demonstrated promising efficacy for lotiglipron in improving glycemic control and inducing weight loss, comparable to the effects expected from its mechanism of action [4], the program was ultimately terminated due to safety concerns.

The emergence of elevated liver transaminases in a subset of patients, although asymptomatic, proved to be an insurmountable safety signal.[1] This liver safety finding, coupled with high rates of gastrointestinal side effects that potentially limited dose escalation [5], rendered the risk-benefit profile unfavorable for chronic use in T2D and obesity.

At the time of lotiglipron's discontinuation in June 2023, Pfizer contrasted its safety profile with that of danuglipron, which reportedly had not shown similar liver enzyme issues in a larger patient cohort.[1] This positioned danuglipron as Pfizer's lead oral GLP-1 RA candidate. However, the subsequent discontinuation of danuglipron development in April 2025, also due to a potential drug-induced liver injury signal [10], suggests potential challenges related either to the specific chemical scaffolds pursued by Pfizer or inherent difficulties in achieving a clean safety profile with small-molecule GLP-1 RAs targeting this complex receptor.

The failure of both lotiglipron and danuglipron significantly impacted Pfizer's strategy in the highly competitive oral GLP-1 RA market, forcing a pivot towards earlier-stage assets or potential external business development activities.[12] For the broader field, these outcomes underscore the difficulty of replicating the success of injectable GLP-1 peptides with oral small molecules, particularly concerning long-term safety profiles, with liver safety emerging as a critical checkpoint.[12] While oral administration offers convenience, ensuring safety comparable to established injectable therapies remains a key challenge for this modality.

In conclusion, lotiglipron (PF-07081532) showed initial promise as a once-daily, oral small-molecule GLP-1 RA with demonstrated efficacy in T2D and obesity. However, its clinical development was halted due to safety concerns, specifically the observation of elevated liver transaminases in clinical trial participants. This outcome highlights the critical importance of rigorous safety evaluation, particularly liver safety, in the development of novel small-molecule drugs for chronic metabolic diseases.

Works cited

1. Pfizer Provides Update on GLP-1-RA Clinical Development Program ..., accessed May 2, 2025, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-glp-1-ra-clinical-development
2. Pfizer Drops Early-Stage Obesity Drug Following Disappointing ..., accessed May 2, 2025, https://www.biospace.com/pfizer-cuts-early-stage-obesity-drug-following-disappointing-phase-i-data
3. Lotiglipron - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 2, 2025, https://synapse.patsnap.com/drug/cb52d1eccf1240689443ee04e0678db6
4. Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies - ResearchGate, accessed May 2, 2025, https://www.researchgate.net/publication/380631299_Once-daily_oral_small-molecule_glucagon-like_peptide-1_receptor_agonist_lotiglipron_PF-07081532_for_type_2_diabetes_and_obesity_Two_randomized_placebo-controlled_multiple-ascending-dose_Phase_1_studie
5. Evaluation of an oral small-molecule glucagon-like peptide-1 ..., accessed May 2, 2025, https://pubmed.ncbi.nlm.nih.gov/39415344/
6. Once-daily oral small-molecule glucagon-like peptide-1 receptor ..., accessed May 2, 2025, https://pubmed.ncbi.nlm.nih.gov/38751362/
7. A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor - PMC, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9234956/
8. Pfizer, citing safety concerns, scraps one of two obesity pill hopefuls | BioPharma Dive, accessed May 2, 2025, https://www.biopharmadive.com/news/pfizer-discontinue-obesity-drug-lotiglipron/653857/
9. Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity, accessed May 2, 2025, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r
10. Pfizer Drops Lead Obesity Asset After Liver Safety Concerns, Overall Review - BioSpace, accessed May 2, 2025, https://www.biospace.com/drug-development/pfizer-drops-lead-obesity-asset-after-liver-safety-concerns-overall-review
11. Pfizer Obesity Pill Abandoned - Perplexity, accessed May 2, 2025, https://www.perplexity.ai/discover/top/pfizer-obesity-pill-abandoned-kh3RaLuiRD2Y5cM8ce83QA
12. Pfizer axes oral GLP-1 asset, blowing hole in obesity plan, accessed May 2, 2025, https://www.fiercebiotech.com/biotech/pfizer-axes-oral-glp-1-asset-over-liver-injury-blowing-hole-obesity-plan
13. Pfizer Stops Work on Oral GLP-1 Obesity Drug After Safety Signal Surfaces in Clinical Trial, accessed May 2, 2025, https://medcitynews.com/2025/04/pfizer-oral-glp-1-obesity-weight-loss-danuglipron-liver-enzymes-pfe/
14. Pfizer Halts Development of Oral Weight-Loss Drug Danuglipron After Safety Concerns, accessed May 2, 2025, https://patrickwareing.com/news/pfizer-halts-development-of-oral-weight-loss-drug-danuglipron-after-safety-concerns/
15. Pfizer drops obesity pill development after liver injury report - Clinical Trials Arena, accessed May 2, 2025, https://www.clinicaltrialsarena.com/news/pfizer-drops-obesity-pill-liver-issue/
16. Pfizer Discontinues Development of Danuglipron for Chronic Weight Management, accessed May 2, 2025, https://www.pharmexec.com/view/pfizer-discontinues-development-danuglipron-chronic-weight-management
17. Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron, accessed May 2, 2025, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist
18. Flagship taps startup to hunt for obesity drugs that might interest Pfizer | BioPharma Dive, accessed May 2, 2025, https://www.biopharmadive.com/news/flagship-profound-pfizer-obesity-protein-drugs/718707/
19. Roche Weighs In With Encouraging Early Clinical Data for Oral GLP-1 Drug - MedCity News, accessed May 2, 2025, https://medcitynews.com/2024/07/roche-oral-glp1-small-molecule-obesity-diabetes-carmot-therapeutics/
20. Pfizer's Once-Daily Weight Loss Pill—Good Play or Bad? - BioSpace, accessed May 2, 2025, https://www.biospace.com/drug-development/pfizers-once-daily-weight-loss-pill-good-play-or-bad
21. Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial, accessed May 2, 2025, https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically